Besselink Marc G H, Timmerman Harro M, van Minnen L Paul, Akkermans Louis M A, Gooszen Hein G
Department of Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Dig Surg. 2005;22(4):234-44. doi: 10.1159/000088053. Epub 2005 Sep 20.
Infectious complications in surgical patients often originate from the intestinal microflora. In the critically ill patient, small bowel motility is disturbed, leading to bacterial overgrowth and subsequent bacterial translocation due to dysfunction of the gut mucosal barrier. The optimal prophylactic strategy should act on all these factors, but such a strategy is not yet available. For several decades, antibiotic prophylaxis to prevent translocation of pathogenic bacteria has been studied with conflicting results. Selective decontamination of the digestive tract has shown good results, but fear for bacterial multiresistance has prevented worldwide implementation. In recent years, probiotics, living bacteria with a potential beneficial effect to their host, have shown promising results in several randomized placebo-controlled trials. Currently, in vitro and experimental research focuses on the effects of probiotics on the microflora responsible for gut-derived infections, structural mucosal barrier function and the immune system.
外科患者的感染并发症通常源于肠道微生物群。在危重症患者中,小肠蠕动受到干扰,导致细菌过度生长,随后由于肠道黏膜屏障功能障碍而发生细菌移位。最佳的预防策略应作用于所有这些因素,但目前尚无这样的策略。几十年来,一直研究使用抗生素预防病原菌移位,结果相互矛盾。消化道选择性去污已显示出良好效果,但对细菌多重耐药性的担忧阻碍了其在全球范围内的应用。近年来,益生菌(对宿主具有潜在有益作用的活菌)在多项随机安慰剂对照试验中显示出了有前景的结果。目前,体外和实验研究聚焦于益生菌对导致肠道源性感染的微生物群、结构性黏膜屏障功能及免疫系统的影响。